PhynovaPhynovaPhynovaPhynova
  • Home
  • About us
    • History
    • Team
      • Board of Directors
      • Management
    • Geographical Presence
    • Careers
  • Products
    • Reducose®
      • Reducose® inside!
      • Protocepts
      • Science News
      • Scientific References
      • Webinars
    • Phynova Joint and Muscle Pain Relief Tablets™
    • Pipeline
  • News
  • Contact us
  • Buy Phynova Joint Pain Relief
  • The Health Blog
NextPrevious

7th clinical trial for Reducose®: new evidence published by Nestlé

By Site Admin | 2022 | Comments are Closed | 6 July, 2022 | 0

Nestlé have published results from a clinical trial evaluating the effect of Reducose® on glucose response following a complete meal. In the study, 30 healthy individuals consumed either 250mg of Reducose® prior to a meal or 250mg Reducose® mixed directly into the meal, with blood glucose measurements recorded every 10 minutes using an Abbott Freestyle Libre continuous glucose monitor (CGM). The results were compared to a control arm that consumed the test meal alone. The study followed a cross-over design, so each subject acted as their own control and participated in all three test groups. This study is the first published clinical trial exploring the effects of Reducose® when taken together with a complete meal (150g rice, 25g white bread, 80g curry sauce, 80g chicken breast) and confirmed the findings of a yet to be published Phynova clinical trial evaluating the effects of Reducose® on glycaemic and insulinaemic responses to a complete meal. The results from the Nestlé study showed significant reduction in the post-prandial glucose (PPG) response to the meal: when taken before the meal, the PPG was lowered by 26% compared with the control arm and lowered by 34% when incorporated directly into the meal. Reducose® also significantly lowered the glucose peak after eating by 28% and 34% respectively. Importantly, Reducose® also optimized the Time-in-Range, the amount of time that the participants blood glucose stayed within optimal blood glucose ranges, with the reported mean glucose values for the Reducose® test groups all being below the recommended maximum postprandial level of 7.8 mmol/L. This study is the first trial to evaluate blood glucose responses using CGMs, highlighting an important benefit of Reducose®: the benefits are immediate and measurable using these new technologies.

nutrients-14-02674-v2
No tags.

NextPrevious

News

  • 2019
  • 2020
  • 2021
  • 2022
  • 2023
  • All
  • Current
  • Healthy Aging
  • Healthy Blood Sugar
  • Ketosis
  • News Stories
  • Popular
  • Reducose products
  • Science of Reducose
  • Uncategorized
  • Upcoming
  • Weight Loss

Contact us

For any queries
Call: +44 (0)1993 880 700
Skype: Phynova Group Ltd
FaceTime: phynova@icloud.com
Email: info@phynova.com

Products

products-icon

Reducose®

Learn more

Joint & Muscle
Relief Tablets™

Learn more

Stay in touch

We would like to hear your views and share
ours with you.
KEEP CONNECTED
© 2021 Phynova Group Ltd | Terms of Use | Privacy Policy | Sitemap | Website by Wiseserve Ltd
  • Home
  • About us
    • History
    • Team
      • Board of Directors
      • Management
    • Geographical Presence
    • Careers
  • Products
    • Reducose®
      • Reducose® inside!
      • Protocepts
      • Science News
      • Scientific References
      • Webinars
    • Phynova Joint and Muscle Pain Relief Tablets™
    • Pipeline
  • News
  • Contact us
  • Buy Phynova Joint Pain Relief
  • The Health Blog
Phynova